CELU (Celularity) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CELU Celularity Inc CELU
31 GF Score
Price $0.81
GF Value $2.32
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Celularity Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CELU
31GF Score
Celularity Inc CELU
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celularity (CELU) Overvalued in 2026?

Based on GuruFocus' analysis, Celularity stock appears to be undervalued. The current stock price of $0.81 is trading 65.1% below its estimated GF Value™ of $2.32. GuruFocus considers Celularity to be Possible Value Trap.

Key valuation signals for CELU:

  • Short Ratio:
  • GF Value™: $2.32 vs. price of $0.81 (65.1% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the CELU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celularity Business Description

Address 170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
31GF Score

Get the complete analysis for CELU

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price
$2.32
GF Value